2L4J
 
 | | Yap ww2 | | Descriptor: | Yes-associated protein 2 (YAP2) | | Authors: | Webb, C, Upadhyay, A, Furutani-Seiki, M, Bagby, S. | | Deposit date: | 2010-10-07 | | Release date: | 2010-11-03 | | Last modified: | 2024-05-01 | | Method: | SOLUTION NMR | | Cite: | Structural Features and Ligand Binding Properties of Tandem WW Domains from YAP and TAZ, Nuclear Effectors of the Hippo Pathway.
Biochemistry, 50, 2011
|
|
4K7C
 | |
9MQJ
 | | Locally-refined Inactive Mu-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #020_E1 | | Descriptor: | Mu-type opioid receptor, methyl (1S,3R,4S,6S,8M)-2-[(1-ethyl-1H-pyrazol-4-yl)methyl]-8-(3-hydroxyphenyl)-3,4-dimethyl-2-azabicyclo[2.2.2]oct-7-ene-6-carboxylate | | Authors: | Kim, J.Y, Vigneron, S.F, Billesbolle, C, Manglik, A, Shoichet, B.K. | | Deposit date: | 2025-01-03 | | Release date: | 2025-02-12 | | Method: | ELECTRON MICROSCOPY (3.23 Å) | | Cite: | Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Biorxiv, 2025
|
|
9MQK
 | | Inactive Kappa-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #020_E1 | | Descriptor: | Kappa-Opioid Receptor, NabFab Heavy Chain, NabFab Light Chain, ... | | Authors: | Kim, J.Y, Vigneron, S.F, Billesbolle, C, Manglik, A, Shoichet, B.K. | | Deposit date: | 2025-01-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | ELECTRON MICROSCOPY (3.18 Å) | | Cite: | Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Biorxiv, 2025
|
|
9MQH
 | | Inactive Mu-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #33 | | Descriptor: | Mu-type opioid receptor | | Authors: | Kim, J.Y, Vigneron, S.F, Billesbolle, C, Manglik, A, Shoichet, B.K. | | Deposit date: | 2025-01-03 | | Release date: | 2025-02-12 | | Method: | ELECTRON MICROSCOPY (3.9 Å) | | Cite: | Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Biorxiv, 2025
|
|
9MQL
 | | Locally-Refined Inactive Kappa-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #020_E1 | | Descriptor: | Kappa-Opioid Receptor, methyl (1S,3R,4S,6S,8M)-2-[(1-ethyl-1H-pyrazol-4-yl)methyl]-8-(3-hydroxyphenyl)-3,4-dimethyl-2-azabicyclo[2.2.2]oct-7-ene-6-carboxylate | | Authors: | Kim, J.Y, Vigneron, S.F, Billesbolle, C, Manglik, A, Shoichet, B.K. | | Deposit date: | 2025-01-03 | | Release date: | 2025-02-12 | | Last modified: | 2025-03-12 | | Method: | ELECTRON MICROSCOPY (2.96 Å) | | Cite: | Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Biorxiv, 2025
|
|
9MQI
 | | Inactive Mu-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #020_E1 | | Descriptor: | Mu-type opioid receptor, NabFab Heavy Chain, NabFab Light Chain, ... | | Authors: | Kim, J.Y, Vigneron, S.F, Billesbolle, C, Manglik, A, Shoichet, B.K. | | Deposit date: | 2025-01-03 | | Release date: | 2025-02-12 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Biorxiv, 2025
|
|
8SUO
 | | BA.2/AZD1061/AZD3152 structure analysis | | Descriptor: | AZD1061 heavy chain, AZD1061 light chain, AZD3152 heavy chain, ... | | Authors: | Oganesyan, V, van Dyk, N, Dippel, A, Barnes, A, O'Connor, E. | | Deposit date: | 2023-05-12 | | Release date: | 2024-05-15 | | Last modified: | 2024-11-27 | | Method: | X-RAY DIFFRACTION (3.3 Å) | | Cite: | AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.
Sci Transl Med, 16, 2024
|
|
